Sweden-based Aerocrine has signed an exclusive agreement with UK & Irish medical device company Healthcare 21 for sales, marketing and distribution of its new airway inflammation monitor and test kit – NIOX VERO – across the UK and Ireland. The agreement goes into effect on 1 February, 2014.

The agreement provides Healthcare 21 exclusive rights for the sales marketing and distribution of Aerocrine’s new instrument NIOX VERO and test kits, used for diagnosing and monitoring patients with asthma.

The deal also includes Healthcare 21 taking on the support, sales and distribution for the already installed base of Aerocrine’s NIOX MINO devices across the UK and Irish market.

Aerocrine vice president international sales and UK general manager David Plotts said as the company continues the roll out of its new product, NIOX VERO in the UK and Ireland; it is delighted to be partnering with Healthcare 21.

"This deal is part of Aerocrine’s strategy of substantially growing the European business in a cost-efficient manner," Plotts added.